Roots Analysis

FEBRUARY 27, 2024

The global genome editing market is anticipated to grow at a CAGR of 12.6% The global genome editing market is anticipated to grow at a CAGR of 12.6% The immense benefits offered by CRISPR makes it one of the most preferred genome editing approach. during the forecast period 2023-2035.

Genome 40

Genome Genomics Gene Gene Editing 40

Pharmaceutical Technology

MAY 25, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

Biobanking 130

Biobanking Genetics Genome Project Genome 130

Drug Discovery World

FEBRUARY 20, 2024

The drug discovery informatics market is predicted to grow from $3.77 The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 52

Marketing Drugs Life Science Genome 52

Outsourcing Pharma

SEPTEMBER 12, 2023

The AstraZeneca-owned company Alexion has teamed up with Verge Genomics to deploy the U.S. startupâs drug discovery platform in the search for novel drug targets for rare neurodegenerative and neuromuscular diseases.

Genome 52

Genome Genomics Drugs Research 52

The Pharma Data

MARCH 7, 2022

Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. IGAs are alterations made using molecular technologies that introduce changes to the genome of an animal. Today, the U.S. Solomon, D.V.M., Related Information.

Genome 52

Genome Genomics Production Marketing 52

Intouch Solutions

NOVEMBER 20, 2023

In the rapidly changing landscape of global markets, staying ahead of the curve is crucial for businesses aiming to expand and thrive. As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors.

Marketing 105

Marketing Manufacturing Genome Genomics 105

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post New podcast: Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Genome Genomics 59

BioTech 365

APRIL 28, 2021

Global Drug Development Market Thematic Research Report 2021: Immuno-oncology, Precision and Personalized, Regenerative, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, and AI – ResearchAndMarkets.com Global Drug Development Market Thematic Research Report 2021: Immuno-oncology, Precision and Personalized, Regenerative, Rare (..)

Genome 40

Genome Genomics Marketing Development 40

Pharmaceutical Technology

JUNE 29, 2022

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

Drugs 246

Drugs FDA Approval Marketing Development 246

Drug Discovery World

JULY 18, 2023

We’re entering a new age of drug discovery, with biological complexity and the development of diagnostic tools to help identify, monitor, and diagnose patients, becoming increasingly important in the creation of novel therapeutics,” said Bryan Kipp, VP/GM, Life Sciences Strategy and Integration. “At

Genome 52

Genome Genomics Life Science Gene Editing 52

Pharmaceutical Technology

JUNE 23, 2022

Researchers at the University of New Hampshire (UNH) have found that a repurposed drug, CCG-50014, could hinder the activity of a key enzyme of the SARS-CoV-2 virus, which causes Covid-19. Utilising a currently available drug compound in a new way is called drug repurposing.

Drugs 130

Drugs Protein Genome Genomics 130

pharmaphorum

JULY 8, 2022

The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and development efforts, and its spend in this area has created a multibillion-dollar market for AI technologies. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

Drugs 131

Drugs Clinical Development Marketing Genome 131

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 52

Development Drugs Genome Genomics 52

BioPharma Reporter

JUNE 23, 2022

BIO, the worldâs largest trade association for the biotech industry, has responded to the US Food and Drug Administration's draft guidance on developing human gene therapy products that incorporate genome editing (GE) of human somatic cells.

Gene Therapy 59

Gene Therapy Genome Genomics Gene 59

Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% respectively compared to an average market growth of 5.8% for the US market 2.

Drugs 59

Drugs Life Science Gene Editing Gene 59

Drug Discovery World

MARCH 7, 2023

DDW Editor Reece Armstrong takes a look at Qatar’s drug discovery and life sciences market, exploring how the country is utilising innovative technologies in its approach to healthcare. The Middle East represents one of the world’s most lucrative markets for pharmaceuticals.

Biobanking 52

Biobanking Drugs Genome Genomics 52

Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. They will also support evidence generation for market access and help clinicians choose the best possible treatments.

Genetics 130

Genetics Development Drugs Genome 130

Drug Discovery World

APRIL 17, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks. Register for free here.

Genome 52

Genome Genomics Gene Expression RNA 52

pharmaphorum

DECEMBER 21, 2021

However, despite the work still left to be done, there are now a growing number of treatments in the pipeline and 2020 proved to be a remarkable year for orphan drug approvals, with the US FDA approving more orphan designated treatments than non-orphan drugs. The potential to leverage genomic data. Headway being made.

Development 98

Development Genome Genomics Drugs 98

Drug Discovery World

APRIL 3, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks. Register for free here.

Genome 52

Genome Genomics Gene Expression RNA 52

Drug Discovery World

AUGUST 24, 2023

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, In the first article, DDW’s Lu Rahman takes a snapshot of the US biotech market and how its successes are having a positive effect on its UK counterpart.

Big Data 52

Big Data Drugs Genome Genomics 52

Drug Discovery World

AUGUST 24, 2023

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, In the first article, DDW’s Lu Rahman takes a snapshot of the US biotech market and how its successes are having a positive effect on its UK counterpart.

Big Data 52

Big Data Drugs Genome Genomics 52

Drug Discovery World

FEBRUARY 6, 2024

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Quris-AI, which combines patient-on-a-chip, AI and real-time nano-sensing technologies to predict the safety and efficacy of drug candidates.

Marketing 69

Marketing Medicine Genome Genomics 69

BioPharma Reporter

MARCH 3, 2022

Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies to market more quickly.

Genome 111

Genome Genomics Marketing Drugs 111

Drug Discovery World

JULY 3, 2023

Emmanuel Abate, President of Genomic Medicine at Cytiva, said: “As pointed out in our 2023 Global Biopharma Resilience Index, collaborations are essential to solve the challenges of bringing future therapeutics to market. We feel lucky to collaborate with such a committed organisation like Cytiva in these efforts.”

Gene Therapy 52

Gene Therapy Gene Marketing Manufacturing 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

FEBRUARY 12, 2024

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. This is part of a series of predictions based on different themes.

Genome 139

Genome Genomics Life Science Gene Therapy 139

Drug Discovery World

FEBRUARY 6, 2024

Her current work focuses on advancing the fields of genome sequencing and analysis, with an emphasis on identifying complex structural variation. She speaks to Megan Thomas on how genomics can advance drug discovery and development. MT: Where is technology being implemented to progress the drug discovery process?

Genome 59

Genome Genomics Genetics In-Vitro 59

Drug Discovery World

APRIL 3, 2023

Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space. You will hear from Darrell Green, a lecturer in (..)

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 24, 2023

The post Free webinar today: How is NGS informing oncology drug discovery? appeared first on Drug Discovery World (DDW). Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space. Register now.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 11, 2023

The post Webinar: Find out how NGS is informing oncology drug discovery appeared first on Drug Discovery World (DDW). Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space. Register now.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 18, 2023

The post Register now to learn how NGS is informing oncology drug discovery appeared first on Drug Discovery World (DDW). Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space. Register now.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 4, 2023

The post Next-generation sequencing and oncology drug discovery appeared first on Drug Discovery World (DDW). Register now.

Drugs 52

Drugs RNA Genome Genomics 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Advantages of Next Generation Sequencing.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Drug Discovery World

FEBRUARY 23, 2024

Despite December usually being a slower time for recruitment, there has been a high number of senior moves within the drug discovery sector over the last three months. They have both worked on or led in the development of multiple drugs within the auto-immune therapeutic area.

Drugs 59

Drugs Life Science Sales Genome 59

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

Drug Discovery World

NOVEMBER 23, 2023

Narain , PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market. We eagerly await future data read-outs from trials because after all, it is the drug that patients are waiting for, not our fancy algorithms. But the utility of biobanks varies.

Biobanking 59

Biobanking Drugs Medicine Genome 59